Molecular Partners AG, which is commercializing a protein scaffold technology, raised CHF46 million (US$44.2 million) in a Series B financing round led by Essex Woodlands Health Ventures, taking its total investment raised in the past two and a half years to CHF64.5 million.(BioWorld International)

No Abstract BioWorld International CorrespondentIntercell AG is strengthening an already solid cash position of €139.7 million (US$203 million) by immediately adding another €62 million, thanks to a wide-ranging strategic alliance with the GSK Biologicials arm of GlaxoSmithKline plc, based on its needle-free, patch-based vaccine in development for travelers' diarrhea and its enhancement patch for pandemic flu vaccines. It also stands to gain a share of the profits from global sales of the two products.

Shares in Movetis NV edged up slightly on their first day of trading on the NYSE Euronext Exchange in Brussels Friday, following an IPO that raised gross proceeds of €85 million (US$126 million). The company priced the offering of 6,938,776 new shares at €12.25, slightly below the mid-point of the indicative range of €11.25 to €14.25 it published at the outset of the book-building period. (BioWorld International)